David Czekai is responsible for drug product development, manufacturing, engineering, and supply chain.
Mr. Czekai is a global pharmaceutical development and operations executive with over 30 years’ experience in advancing complex, technology-based products from proof of concept through commercialization. He is a pioneer in the areas of developing and advancing nanotechnology to commercial success for multiple FDA/EMA-approved drug products. Mr. Czekai started his career at Eastman Kodak where he was co-inventor of Kodak’s NanoCrystal® technology platform, and co-founder of Kodak’s pharmaceutical subsidiary NanoSystems LLC (later acquired by Elan Corporation). While at Elan (later acquired by Alkermes), Mr. Czekai led the NanoCrystal® business, including drug delivery, product development, and commercialization within the global pharmaceutical industry.
After his tenure at Alkermes, he founded and served as president of NanoCentrix LLC, a pharmaceutical nanotechnology development and consulting business.
Mr. Czekai holds over 30 US Patents in the fields of pharmaceuticals and nanotechnology. Mr. Czekai earned his B.S. and M.S. degrees in chemical engineering from Clarkson University and has been inducted to Omega Chi Epsilon and Tau Beta PI National Engineering Honor Societies.